Patents Examined by Brian R. Stanton
  • Patent number: 6452066
    Abstract: Several genes encoding subunits of the neuronal nicotinic acetylcholine receptors have been cloned and regulatory elements involved in the transcription of the &agr;:2 and &agr;:7- subunit genes have been described. Yet, the detailed mechanisms governing the neuron-specific transcription and the spatio-temporal expression-pattern of these genes remain largely uninvestigated. The &bgr;2-subunit is the most widely expressed neuronal nicotinic receptors subunit in the nervous system. We have studied the structural and regulatory properties of the 5′ sequence of this gene. A fragment of 1163 bp of upstream sequence is sufficient to drive the cell-specific transcription of a reporter gene in both transient transfection assays and in transgenic mice. Deletion analysis and site-directed mutagenesis of this promoter reveal two negative and one positive element. The positively acting sequence includes one functional E-box.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 17, 2002
    Assignee: Institut Pasteur
    Inventors: Jean-Pierre Changeux, Marina Picciotto, Alain Bessis
  • Patent number: 6368572
    Abstract: A chimeric non-human mammal M3 having its hematopoietic cells substantially destroyed and replaced by hematopoietic cells from a hematopoietic deficient mammal, wherein M3 is susceptible to bacterial toxin-related pathologies found in humans, and to methods of making and using thereof.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: April 9, 2002
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, George Lowell, Esther Aboud-Pirak
  • Patent number: 6133502
    Abstract: Provided is a non-human animal in which an exogeneous gene, a mutant gene thereof of a monocyte chemoattractant protein and/or a receptor thereof is introduced. The present transgenic animals can be utilized as a pathologic model animal for heart diseases, respiratory diseases, joint diseases, kidney diseases, arteriosclerosis, psoriasis, hyperlipidemia, allergic diseases, bone diseases, blood diseases, cerebrovascular disorders, traumatic cerebral disorders, infections diseases, demantia or chroric inflammatory diseases etc. Thus, it is possible to elucidate the mechanism of pathogenesis of these diseases, to determine therapies, and to screen for candidate compounds for the purpose of research and development of therapeutic drugs.
    Type: Grant
    Filed: March 9, 1998
    Date of Patent: October 17, 2000
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Hisao Kasuga, Takahito Kitayoshi, Masami Isaka
  • Patent number: 6114598
    Abstract: The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by multiple genetic modifications of embryonic cells in conjunction with breeding. Different strategies are employed for recombination of the human loci randomly or at analogous host loci. Chimeric and transgenic mammals, particularly mice, are provided, having stably integrated large, xenogeneic DNA segments. The segments are introduced by fusion with yeast spheroplasts comprising yeast artificial chromosomes (YACs) which include the xenogeneic DNA segments and a selective marker such as HPRT, and embryonic stem cells.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: September 5, 2000
    Assignee: Abgenix, Inc.
    Inventors: Raju Kucherlapati, Aya Jakobovits, Sue Kalpholz, Daniel G. Brenner, Daniel J. Capon
  • Patent number: 6090620
    Abstract: The present invention discloses nucleic acid molecules encoding WRN gene products, expresion vectors, viral vectors, and host cells suitable for expressing such products.
    Type: Grant
    Filed: December 27, 1996
    Date of Patent: July 18, 2000
    Assignee: University of Washington
    Inventors: Ying-Hui Fu, Chang-En Yu, Junko Oshima, John T. Mulligan, Gerard D. Schellenberg
  • Patent number: 6069134
    Abstract: The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in combination with a chemotherapeutic agent. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into tumors subcutaneously, followed by intraperitoneal administration of a DNA damaging agent, cisplatin, induced massive apoptotic destruction of the tumors. The invention also provides for the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.
    Type: Grant
    Filed: October 17, 1997
    Date of Patent: May 30, 2000
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jack A. Roth, Toshiyoshi Fujiwara, Elizabeth A. Grimm, Tapas Mukhopadhyay, Wei-Wei Zhang, Laurie B. Owen-Schaub
  • Patent number: 6054298
    Abstract: Isolated DNA encoding a protein or polypeptide having at least one biological activity of a vertebrate fringe protein, as well as the protein or polypeptide encoded thereby, are described. Assays for identifying agents which alter the expression of the described fringe genes and assays for agents which alter the production of angiogenic precursors, the formation of the apical ectodermal ridge and the subdivisions of the neural tube are also described.
    Type: Grant
    Filed: January 16, 1996
    Date of Patent: April 25, 2000
    Assignee: President and Fellows of Harvard College
    Inventors: Edward M. Laufer, Olivia E. Orozco, Clifford J. Tabin
  • Patent number: 6051559
    Abstract: A method of regulating long term memory is disclosed. Also disclosed is isolated DNA encoding a cyclic 3',5'-adenosine monophosphate responsive transcriptional activator, isolated DNA encoding an antagonist of cyclic 3',5'-adenosine monophosphate-inducible transcription, isolated DNA encoding an enhancer-specific activator, and isolated DNA encoding a nitric oxide synthase. A method for assessing the effect of a drug on long term memory formation is also disclosed.
    Type: Grant
    Filed: December 21, 1994
    Date of Patent: April 18, 2000
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Timothy P. Tully, Jerry Chi-Ping Yin
  • Patent number: 6040296
    Abstract: A DNA comprises an oligonucleotide antisense to mRNA encoding an adenosine A.sub.1 or A.sub.3 receptor. The oligo is provided as a composition, various formulations, a capsule, and cartridge and in the form of a kit. The oligonucleotide of the invention is effective for reducing bronchoconstriction and/or allergy, and may be administered to a subject to treat respiratory ailments such as asthma and other conditions associated with the expression of adenosine receptors.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 21, 2000
    Assignee: East Carolina University
    Inventor: Jonathan W. Nyce
  • Patent number: 6031150
    Abstract: The present invention is directed to a method of detecting persistent hyperinsulinemic hypoglycemia of infancy comprising obtaining a sample comprising patient nucleic acids from a patient tissue sample; amplifying sulfonylurea receptor specific nucleic acids from said patient nucleic acids to produce a test fragment; obtaining a sample comprising control nucleic acids from a control tissue sample; amplifying control nucleic acids encoding wild type sulfonylurea receptor to produce a control fragment; comparing the test fragment with the control fragment to detect the presence of a sequence difference in the test fragment, wherein a difference in said test fragment indicates persistent hyperinsulinemic hypoglycemia of infancy. A diagnostic kit and primers for the detection of persistent hyperinsulinemic hypoglycemia of infancy are also within the scope of the present invention.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 29, 2000
    Assignee: Baylor College Of Medicine
    Inventors: Joseph Bryan, Lydia Aguilar Bryan, Daniel Nelson
  • Patent number: 6027935
    Abstract: The novel gene, Rasp-1, which is up-regulated in regenerating liver, is disclosed. The novel RASP-1 protein, which is encoded by the Rasp-1 gene, is also disclosed. In addition, antibodies against the Rasp-1 gene products are also disclosed. Furthermore, the use of Rasp-1 nucleic acid sequences, Rasp-1 gene products, and antibodies against Rasp-1 gene products in the treatment and diagnosis of liver disorders is also disclosed.
    Type: Grant
    Filed: June 5, 1996
    Date of Patent: February 22, 2000
    Assignee: Advanced Tissue Sciences, Inc.
    Inventors: Anthony F. Purchio, Liguo New, Kang Liu, Vafa Kamali, Brian Naughton
  • Patent number: 6025339
    Abstract: A method of reducing bronchoconstriction in a subject in need of such treatment is disclosed. The method comprises administering to the subject an antisense oligonucleotide molecule directed against the A.sub.1 or A.sub.3 adenosine receptor in an amount effective to reduce bronchoconstriction. The method is useful for treating patients afflicted with asthma. Pharmaceutical formulations are also disclosed.
    Type: Grant
    Filed: November 26, 1996
    Date of Patent: February 15, 2000
    Assignee: East Carolina University
    Inventor: Jonathan W. Nyce
  • Patent number: 6025337
    Abstract: A target-specific gene delivery system is made of enzymatically degradable gelatin and nucleic acids (DNA or RNA) microparticles with a linking moiety or a targeting ligand attached to the surface. The delivery system can be made by a simple method. Targeting ligands can be attached to the microparticle directly or via a linking moiety. The linkage design allows the attachment of any molecule onto the microparticle surface including antibodies, cell adhesion molecules, hormones and other cell-specific ligands.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: February 15, 2000
    Assignee: Johns Hopkins University
    Inventors: Vu L. Truong, Thomas August, Kam W. Leong
  • Patent number: 6022736
    Abstract: The present invention provides novel recombinant nucleic acid vectors which may be used to produce .alpha.-globin as well as other proteins of interest in quantity in the red blood cells of transgenic animals or cell cultures of erythroid lineage. The present invention also provides for the transgenic animals which contain these recombinant nucleic acid vectors. The vectors of the invention comprise at least one of the major DNase I hypersensitivity sites associated with the .beta.-globin locus together with a gene of interest. According to various embodiments of the invention, the vectors may be used to create transgenic animals or to transfect cells in culture. In a specific embodiment of the invention, a vector which comprises two DNase I hypersensitivity sites together with the human .alpha.-globin gene is used to create transgenic animals which produce human .alpha.-globin protein in erythroid tissues, including red blood cells.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 8, 2000
    Assignees: The UAB Research Foundation, The Trustees of the University of Pennsylvania, Board of Regents of the University of Washington
    Inventors: Tim M. Townes, Thomas M. Ryan, Richard D. Palmiter, Ralph L. Brinster, Richard R. Behringer
  • Patent number: 6022735
    Abstract: A composition for the transfection of higher eucaryotic cells, comprising complexes of nucleic acid, a substance having an affinity for nucleic acid and optionally an internalizing factor, contains an endosomolytic agent, e.g. a virus or virus component, which may be conjugated. The endosomolytic agent, which is optionally part of the nucleic acid complex, is internalized into the cells together with the complex and releases the contents of the endosomes into the cytoplasm, thereby increasing the gene transfer capacity. Pharmaceutical preparations, transfection kits and methods for introducing nucleic acid into higher eucaryotic cells by treating the cells with the composition are also disclosed.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: February 8, 2000
    Assignees: Boehringer Ingelheim International GmbH, Genetech, Inc., The University of North Carolina at Chapel Hill
    Inventors: David T. Curiel, Max L. Birnstiel, Matthew Cotten, Ernst Wagner, Kurt Zatloukal, Christian Plank, Berndt Oberhauser, Walter G. M. Schmidt
  • Patent number: 6020201
    Abstract: A protein having polysialyl transferase activity, which a) is a product of a prokaryotic or eukaryotic expression of an exogenous DNA, b) is coded by the DNA sequence shown in SEQ ID No. 1, c) is coded by the DNA sequences which hybridize with the sequences SEQ ID No. 1 and/or SEQ ID No. 3, d) is coded by DNA sequences which if there was no degeneracy of the genetic code, would hybridize with the sequences defined in b) to c), and e) catalyzes the polycondensation of .alpha.-2,8-linked sialic acids, and its related nucleic acid molecules and fragments are useful for the production of therapeutic agents for tumor therapy.
    Type: Grant
    Filed: July 24, 1997
    Date of Patent: February 1, 2000
    Assignee: Boehringer Mannheim GmbH
    Inventors: Rita Gerardy-Schahn, Minoru Fukuda, Jun Nakayama, Matthias Eckhardt
  • Patent number: 6018096
    Abstract: A chimeric, non-human, genetically-immunocompetent mammal is disclosed. The hematopoietic system of the mammal has human passaged bone marrow stromal cells and human hematopoietic stem cells obtained from a CD34.sup.+ -enriched bone marrow fraction, and also contains transplanted syngeneic non-lymphoid spleen colony cells. The mammal may be a mouse, a rat, a rabbit, a cat, a dog, a pig, a sheep or a non-human primate. The mammal can be produced by providing a non-human, genetically-immunocompetent mammal in which its immunologic genotype comports with the norm for the species of the mammal, exposing the mammal to a level of x- or gamma-radiation that is sufficient to destroy substantially all bone marrow in the mammal to render the mammal phenotypically immunodeficient, then transplanting into the mammal syngeneic non-lymphoid spleen colony cells and human passaged bone marrow stromal cells, and transplanting into the mammal human hematopoietic stem cells obtained from a CD34.sup.
    Type: Grant
    Filed: May 3, 1993
    Date of Patent: January 25, 2000
    Assignee: Surrogen, Inc.
    Inventors: Armand Keating, Dong-dong Wu
  • Patent number: 6015687
    Abstract: The present invention provides a novel family of apoptosis-modulating proteins. Nucleotide and amino acid residue sequences and methods of use thereof are also provided.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 18, 2000
    Assignee: LXR Biotechnology Inc.
    Inventors: Michael C. Kiefer, Philip J. Barr
  • Patent number: 6010694
    Abstract: Human fibroblast cells that comprise a gene construct that comprises a duplication mutated fibrillin 1 gene operably linked to functional regulatory elements and compositions comprising such cells are disclosed. Methods of treating wounds and kits for practicing such methods are disclosed. Transgenic animals comprising a duplication mutated fibrillin 1 gene operably linked to a tissue specific and/or inducible promoter are disclosed. Methods of identifying individuals with a duplication mutated fibrillin 1 gene are disclosed. The methods comprises detecting a duplication of exons 17-40 of a fibrillin 1 gene or a gene product produced by expression of a duplication mutated fibrillin 1 gene. Methods of preventing expression of a duplication mutated fibrillin 1 gene are disclosed.
    Type: Grant
    Filed: July 26, 1996
    Date of Patent: January 4, 2000
    Assignee: Thomas Jefferson University
    Inventors: Linda D. Siracusa, Sergio A. Jimenez
  • Patent number: 6001990
    Abstract: The invention features antisense oligonucleotides and methods of using these antisense oligonucleotides for inhibiting HCV RNA translation.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 14, 1999
    Assignee: The General Hospital Corporation
    Inventors: Jack R. Wands, Takaja Wakita, Darius Moradpour